Characterization of Immune Response to Vaccination in Patients Receiving Single-Drug Immunosuppressive Therapy
N/A
18 Years
89 Years
18 Years
89 Years
Open (Enrolling)
Both
Immunosuppression
Both
Immunosuppression
Trial Information
Characterization of Immune Response to Vaccination in Patients Receiving Single-Drug Immunosuppressive Therapy
Inclusion Criteria:
- 18 years or older
- Patient Taking azathioprine, Humira, Enbrel or Remicade
- Willing to participate in the healthy volunteer arm
Exclusion Criteria:
- Has received flu vaccine in past year
- Taking steroids or any other immunosuppressive drug
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Specific Aim 1: Characterize influenza antibody titers before and after vaccination in patients taking azathioprine, TNF-alpha, or in healthy controls.
Outcome Description:
Specific Aim 1: Characterize influenza antibody titers before and after vaccination in patients taking azathioprine, TNF-alpha, or in healthy controls.
Outcome Time Frame:
1 year
Safety Issue:
Yes
Authority:
United States: Institutional Review Board
Study ID:
Emory IRB00044264
NCT ID:
NCT01733056
Start Date:
January 2011
Completion Date:
Related Keywords:
- Immunosuppression
- Dermatology
- Influenza Vaccine
Name | Location |
|---|---|
| Emory University, Department of Dermatology | Atlanta, Georgia 30322 |
